跳至主要内容
临床试验/NCT02830750
NCT02830750已完成不适用

A Multi Center Registry of Low- Fluoroscopy Atrial Fibrillation Ablation Using Electroanatomic Mapping Carto

Stanford University2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2016年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
160
试验地点
2
主要终点
Atrial Fibrillation

研究概览

简要总结

Prospective data collection of patients undergoing Atrial Fibrillation Ablation.

详细描述

Clinicians who have experience using low dose fluoroscopy including use of Carto Mapping system will consent patients to allow data collection and a 12 month f/up visit to track adverse events. Clinicians will follow a protocol which will be similar to their standard of care for ablations.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient meets accepted AHA/ACC/HRS guideline indications for catheter ablation of paroxysmal or persistent AF
  • First or subsequent ablation procedures may be included
  • Age 18-75

排除标准

  • Known venous malformations or implanted instrumentation (IVC filter)
  • Known PV stenosis
  • Unable to provide consent
  • H/O mechanical mitral valve replacement (unable to rely on EA mapping only)
  • Documented left atrial thrombus
  • Prior ASD repair Pregnancy
  • NYHA >=3
  • EF less than 35%
  • CHF within 90 daysRecent MI or coronary revascularization within 90 days
  • NOTE: H/O implanted pacemaker or ICD with transvenous leads will NOT be an exclusion criteria, but we will track patients treated with pre-existing transvenous leads with the hypothesis that although fluoroscopy use will be higher in these patients compared to those without leads, but still lower than conventionally treated patients.
  • Patients who are undergoing non- standard of care ablations ie, Cyro or FIRM ablations

结局指标

主要结局

Atrial Fibrillation

时间窗: 12 months

Determine Atrial Fibrillation burden at 12 month visit by reviewing monitoring systems that capture this data

次要结局

  • Fluoroscopic Usage(post operative)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gerri O'Riordan

Direcetor of Clinical Resarch. CV Med

Stanford University

研究点 (2)

Loading locations...

相似试验